Segment Data (Tables)

6 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and six-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended March 31,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	588	$	450	$	1,038	$	531	$	468	$	999
Medication Management Solutions	461		143		604		440		126		566
Diabetes Care	140		133		273		148		135		284
Pharmaceutical Systems	125		376		501		100		361		462
Total segment revenues	$	1,314	$	1,102	$	2,416	$	1,220	$	1,091	$	2,311
Life Sciences
Integrated Diagnostic Solutions	$	618	$	532	$	1,150	$	454	$	807	$	1,261
Biosciences	129		206		335		121		204		325
Total segment revenues	$	747	$	738	$	1,485	$	576	$	1,010	$	1,586
Interventional
Surgery	$	268	$	72	$	340	$	227	$	65	$	292
Peripheral Intervention	240		210		450		222		198		420
Urology and Critical Care	239		82		320		217		82		298
Total segment revenues	$	746	$	364	$	1,111	$	666	$	345	$	1,011
Total Company revenues	$	2,807	$	2,204	$	5,011	$	2,462	$	2,446	$	4,907

	Six Months Ended March 31,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	1,207	$	915	$	2,122	$	1,099	$	908	$	2,006
Medication Management Solutions	945		286		1,231		917		278		1,196
Diabetes Care	291		271		561		298		271		569
Pharmaceutical Systems	228		670		898		180		621		801
Total segment revenues	$	2,671	$	2,142	$	4,813	$	2,494	$	2,078	$	4,572
Life Sciences
Integrated Diagnostic Solutions	$	1,232	$	1,062	$	2,295	$	1,469	$	1,459	$	2,928
Biosciences	258		416		674		241		396		637
Total segment revenues	$	1,490	$	1,478	$	2,968	$	1,710	$	1,855	$	3,565
Interventional
Surgery	$	549	$	152	$	701	$	489	$	135	$	624
Peripheral Intervention	457		407		863		454		392		846
Urology and Critical Care	492		168		661		445		171		616
Total segment revenues	$	1,498	$	727	$	2,225	$	1,388	$	698	$	2,086
Total Company revenues	$	5,659	$	4,347	$	10,006	$	5,592	$	4,631	$	10,223

Financial Information for Company's Segments

Segment income for the three and six-month periods was as follows:

	Three Months Ended March 31,				Six Months Ended March 31,
(Millions of dollars)	2022		2021		2022		2021
Income Before Income Taxes
Medical (a)	$	615	$	634	$	1,331	$	1,300
Life Sciences	475		548		1,009		1,521
Interventional	280		209		544		511
Total Segment Operating Income	1,370		1,392		2,884		3,331
Integration and restructuring expense	(28)		(52)		(62)		(102)
Net interest expense	(100)		(122)		(195)		(238)
Other unallocated items (b)	(717)		(913)		(1,378)		(1,529)
Total Income Before Income Taxes	$	525	$	305	$	1,248	$	1,462

(a)The amounts for the three and six months ended March 31, 2022 include a noncash asset impairment charge of $54 million recorded to Cost of products sold in the Medical segment.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amounts for the three and six months ended March 31, 2021 also included pre-tax charges of $296 million recorded to Other operating expense, net related to certain product liability matters, including the related legal defense costs, which are further discussed in Note 4.